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METHODS: Five renal centres were investigated. All resources
used during the process of dialysis treatment were identiﬁed
during semi-structured interviews; published costs were applied.
Overhead costs were apportioned using standard cost account-
ing. RESULTS: Annual costs of HD in main units ranged from
£33,516 to £45,029 (£30,508 to £46,459 in satellite units). A
key differential factor between the units was the overhead costs.
HD costs without overheads ranged from £30,055 to £35,138
(£23,110 to £35,227 in satellite units). Annual costs of PD were
£14,859 to £17,022 and £22,196 to £24,358 for CAPD and
APD, respectively. The key differential cost drivers between HD
and PD other than overheads were disposables (averaging
£10,117 for HD, £9,349 for CAPD and £16,223 for APD),
nursing (£9,921 for HD; £2,775 for PD), anaemia therapy
(£7,005 for HD; £2,410 for PD) and transport (£2,352 for HD;
£130 for PD). CONCLUSION: Within individual renal centres,
the costs of delivering APD range from 32% to 50% lower than
HD and for CAPD costs are from 53% to 66% lower than HD.
Increased use of PD could result in more efﬁcient use of resources
from the perspective of purchasers and the government. More-
over, this type of treatment aligns with the UK government’s
strategy of patient choice and self-care in a home environment.
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OBJECTIVES: To quantify and compare staff time related to
anaemia management with currently available ESA drugs in hae-
modialysis centres and to model the potential efﬁciency gains
with adoption of once-monthly C.E.R.A. (continuous erythro-
poietin receptor activator) injections. METHODS: A multicen-
tre, prospective, activity-based costing study was undertaken in
17 dialysis centres across 3 countries. Tasks were grouped into
observable tasks (ESA preparation and administration) and
quantiﬁed through time and motion observations. Time for non-
observable tasks (e.g. ESA inventory/ordering, blood sampling,
physician review) was estimated through staff interviews. Time
was translated into cost using estimates of national wages for
personnel. ESA acquisition costs were excluded. RESULTS:
Average observed time and cost per ESA administration was 1.67
minutes (€0.53) in Germany, 2.67 minutes (€1.55) in the UK and
2.35 minutes (€1.92) in the US. Time per patient per year varies
primarily due to the different mix of products and their frequency
of administrations. The weighted average number of ESA injec-
tions per patient per week (year) was 1.8 (94) across the German
centres, 1.6 (83) in the UK and 3 (155) in the US centres. Time for
non observable tasks account for 40 to 60% of the total time
related to anaemia activities. Modelling estimated that with
once-monthly C.E.R.A time for the observed activities would be
28 to 32 minutes per patient per year (>80% reduction). Addi-
tional savings could be generated related to non-observable
tasks. The order of magnitude of these savings may vary ac-
cording to the organization of the centres. CONCLUSIONS:
Anaemia management with ESAs appears fairly standardized
across dialysis centres and countries and accounts for a signiﬁ-
cant amount of staff time. With 12 injections of C.E.R.A. per
patient per year, substantial time savings could be achieved
enabling centres to focus on other aspects of patient care.
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OBJECTIVES: Hyperphosphatemia is associated with increased
mortality and morbidity for patients with chronic kidney disease
who receive dialysis. Treatments for hyperphosphatemia include
calcium- and other metal-based binders. However, metal-based
binders are associated with increased calciﬁcation, which is likely
to results in greater rates of complications and reduced survival.
This analysis compares the use of sevelamer, a non-metal-based
phosphate binder against calcium binders. The objective was to
estimate the costs and health outcomes associated with sevelamer
for treatment of hyperphosphatemia compared with calcium-
based binders in patients new to dialysis over ﬁve years, from the
perspective of the National Health Service in the UK. The model
was also adapted to three other European countries: Finland,
Poland and Germany. METHODS: A ﬁve-year deterministic
decision analysis model was designed in order to estimate and
compare the costs and outcomes of treatment with sevelamer
versus calcium acetate. The model used Markov techniques to
predict the monthly changes in health status (including inpatient
stay and survival). Mortality rates and hospitalisation rates were
drawn from published sources and patients using sevelamer had
a 79% risk reduction of hospitalizations for the ﬁrst 18 months
of the model. Costs were limited to those incurred by the health
care provider, and were drawn from national databases.
RESULTS: The total ﬁve-year discounted treatment cost for
patients treated with sevelamer is 24,216 compared to
17,985 for calcium acetate. Patients receiving sevelamer can be
expected to experience 2.70 quality-adjusted life years (QALYs)
compared to 2.46 for those treated with calcium acetate. The
incremental cost-effectiveness ratio (ICER) for sevelamer was,
therefore, 25,916 per QALY. CONCLUSION: Sevelamer pro-
vides unique therapeutic beneﬁts including a signiﬁcant relative
risk reduction in mortality and morbidity. As demonstrated in
this economic evaluation, the reduction in mortality and mor-
bidity translates into a substantial QALY gain with a modest
investment of additional economic resources.
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OBJECTIVES: The worldwide incidence of kidney failure con-
tinues to rise and treatment is costly; therefore, the burden of
illness, including the health care resources allocated to its treat-
ment, is growing. Given that the number of end-stage renal
disease (ESRD) patients is increasing and the majority is on some
form of dialysis, the number of dialysis patients is expected to
increase as well. The purpose of this assessment was to review
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